|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2000-5-19
|
|
pubmed:abstractText |
Cardiopulmonary bypass (CPB) initiates a whole-body inflammatory response where complement and neutrophil activation and cytokine release play an important role. This prospective trial examined the effects of both heparin-coated circuits and aprotinin on the inflammatory processes during CPB, with respect to cytokine release and neutrophil activation.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0003-4975
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
69
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1084-91
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10800798-Aprotinin,
pubmed-meshheading:10800798-Cardiopulmonary Bypass,
pubmed-meshheading:10800798-Coated Materials, Biocompatible,
pubmed-meshheading:10800798-Cytokines,
pubmed-meshheading:10800798-Female,
pubmed-meshheading:10800798-Fibrinolytic Agents,
pubmed-meshheading:10800798-Hemostatics,
pubmed-meshheading:10800798-Heparin,
pubmed-meshheading:10800798-Humans,
pubmed-meshheading:10800798-Interleukin-6,
pubmed-meshheading:10800798-Interleukin-8,
pubmed-meshheading:10800798-Male,
pubmed-meshheading:10800798-Middle Aged,
pubmed-meshheading:10800798-Neutrophil Activation,
pubmed-meshheading:10800798-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Cytokine release and neutrophil activation are not prevented by heparin-coated circuits and aprotinin administration.
|
|
pubmed:affiliation |
Department of Cardiovascular Surgery, University Hospital of Liège, Belgium. jo.defraigne@chu.ulg.ac.be
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|
